In reply to: I am a physician and think its posted by panamirish
it encodes a stabilized part of the spike protein but it is a viral vector and not mRNA
sequences and not mRNA. Merck has an inactivated viral vaccine that got shelved. The Russians have one, they didn’t do phase 3 testing on but went straight from phase 2 to human use, from what I understand, as do the Chinese.
is allegedly just the stolen Johnson & Johnson vaccine.
viruses altered chemically or irradiated to attenuate them and they skipped the 3rd phase of trials- proof of prevention in humans. They could have stolen J and Js but it takes time to grow and process all those tiny proteins. Much faster to steal an mRNA vaccine recipe, I think. Unless of course you just steal a shipment of vaccine.
"In the past, it has taken years, even decades, to bring new vaccines to market. Attenuated vaccines, such as those for measles, mumps, and rubella, involve weakening a virus to non-dangerous strength; inactivated vaccines, as in most flu shots, render it inert. Developing such vaccines is a tricky process of trial and error. Research into mRNA vaccines—which, in contrast to traditional vaccines, are synthetic, carrying a portion of a virus’s genetic code—began in the nineteen-nineties. Though the mRNA technology was unproved until last year, it was also tantalizingly simple, akin to programming a script of computer software. Moderna, a pharmaceutical company founded in 2010 with a focus on mRNA, created its vaccine prototype during a weekend in January, 2020. In mid-March, the pharmaceutical giant Pfizer, working with the German company BioNTech, came up with twenty contenders for a vaccine; by early April, they had been whittled down to four.
Sputnik V—like several other covid-19 vaccines, developed by Oxford University and AstraZeneca, in the United Kingdom; CanSino Biologics, in China; and Johnson & Johnson, in the United States—is what is known as a vector vaccine. This type of vaccine is much newer than the attenuated or inactivated kind but has a longer track record than the mRNA variety."